Back
 OJCD  Vol.9 No.1 , March 2019
Clinical and Technological Dependence Characteristics on a Series of Brazilian Cases with Infantile Onset Pompe Disease in Enzyme Replacement Therapy
Abstract: Pompe disease (PD) is a rare inborn error of metabolism due to an abnormal acid alpha-glucosidase (GAA) activity that comprises glycogen breakdown mainly in the lysosomes. Since the introduction of enzyme replacement therapy (ERT), with recombinant human GAA for the early onset PD patient, a relevant field of clinical research due to the benefits regarding survival rate has been widely documented worldwide. Objective: To describe the clinical characteristics and the ERT effects in a series of Brazilian patients with infantile onset PD (IOPD) under ERT. Methods: Brazilian patients diagnosed with IOPD under ERT were recruited through their physicians participating in the International Pompe Disease Registry from 2009 to 2017. Data were collected by an online survey. Results: 10 IOPD patients were identified through the survey with a death rate of 30% and technology dependency rate reported as 80% (motor, respiratory or nutritional fields) of the patients. After the third year of ERT, motor disabilities were lost in 50% of ambulated patients. The overall characteristics were similar to international studies. Conclusion: Despite ERT benefits in cardiac involvement, motor disabilities seem to be much more compromised in IOPD patients, with high technology dependence, especially after three years of age.
Cite this paper: Thomazinho, P. , Pelissari, E. , Duarte, R. , De Souza, C. , Borges, H. , Horta, M. , Giuliani, L. , Martins, A. , Stewart, L. , Horovitz, D. and Llerena, J. (2019) Clinical and Technological Dependence Characteristics on a Series of Brazilian Cases with Infantile Onset Pompe Disease in Enzyme Replacement Therapy. Open Journal of Clinical Diagnostics, 9, 16-32. doi: 10.4236/ojcd.2019.91002.
References

[1]   Kishnani, P.S., Amartino, H.M., Lindberg, C., Miller, T.M., Wilson, A., Keutzer, J., et al. (2014) Methods of Diagnosis of Patients with Pompe Disease: Data from the Pompe Registry. Molecular Genetics and Metabolism, 113, 84-91.
https://doi.org/10.1016/j.ymgme.2014.07.014

[2]   Hahn, S.H., Kronn, D., Leslie, N.D., Pena, L.D.M., Tanpaiboon, P., Gambello, M.J., et al. (2018) Efficacy, Safety Profile, and Immunogenicity of Alglucosidase Alfa Produced at the 4,000-Liter Scale in US Children and Adolescents with Pompe Disease: ADVANCE, a Phase IV, Open-Label, Prospective Study. Genetics in Medicine, 20, 1284-1294.
https://doi.org/10.1038/gim.2018.2

[3]   Raben, N., Wong, A., Ralston, E. and Myerowitz, R. (2012) Autophagy and Mitochondria in Pompe Disease: Nothing Is So New as What Has Long Been Forgotten. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160C, 13-21.
https://doi.org/10.1002/ajmg.c.31317

[4]   Raben, N., Ralston, E., Chien, Y.H., Baum, R., Schreiner, C., Hwu, W.L., Zaal, K.J. and Plotz, P.H. (2010) Differences in the Predominance of Lysosomal and Autophagic Pathologies between Infants and Adults with Pompe Disease: Implications for Therapy. Molecular Genetics and Metabolism, 101, 324-331.
https://doi.org/10.1016/j.ymgme.2010.08.001

[5]   Raval, K.K., Tao, R., White, B.E., et al. (2015) Pompe Disease Results in a Golgi-based Glycosylation Deficit Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. The Journal of Biological Chemistry, 290, 3121-3136.
https://doi.org/10.1074/jbc.M114.628628

[6]   Kishnani, P.S., Goldenberg, P.C., DeArmey, S.L., Heller, J., Benjamin, D., Young, S., et al. (2010) Cross-Reactive Immunologic Material Status Affects Treatment Outcomes in Pompe Disease Infants. Molecular Genetics and Metabolism, 99, 26-33.
https://doi.org/10.1016/j.ymgme.2009.08.003

[7]   Kishnani, P.S., Steiner, R.D., Bali, D., Berger, K., Byrne, B.J., Case, L.E., The ACMG Work Group on Management of Pompe Disease, et al. (2006) Pompe Disease Diagnosis and Management Guidelines. Genetics in Medicine, 8, 267-288.
https://doi.org/10.1097/01.gim.0000218152.87434.f3

[8]   Howell, R.R., Byrne, B., Darras, B.T., Kishnani, P.S., Nicolino, M. and van der Ploeg, A.T. (2006) Diagnostic Challenges for Pompe Disease: An Underrecognized Cause of Floppy Baby Syndrome. Genetics in Medicine, 8, 289-296.
https://doi.org/10.1097/01.gim.0000204462.42910.b8

[9]   Llerena Junior, J.C., Horovitz, D.M., Marie, S.K.N., Porta, G., Giugliani, R., Rojas, M.V.M., et al. (2009) The Brazilian Consensus on the Management of Pompe Disease. Journal of Pediatrics, 155, S47-S56.
https://doi.org/10.1016/j.jpeds.2009.07.006

[10]   Llerena Junior, J.C., Nascimento, O.J.M., Oliveira, A.S.B., Dourado Junior, M.E.T., Marrone, C.D., Siqueira, H.H., et al. (2015) Guidelines for the Diagnosis, Treatment and Clinical Monitoring of Patients with Juvenile and Adult Pompe Disease. Arquivos de Neuro-Psiquiatria, 74, 166-176.

[11]   Prater, S.N., Banugaria, S.G., De Armey, S.M., Botha, E.G., Case, L.E., Jones, H.N., et al. (2012) The Emerging Phenotype of Long-Term Survivors with Infantile Pompe Disease. Genetics in Medicine, 14, 800-810.
https://doi.org/10.1038/gim.2012.44

[12]   Case, L.E., Beckemeyer, A.A. and Kishnani, P.S. (2012) Infantile Pompe Disease on ERT—Update on Clinical Presentation, Musculoskeletal Management, and Exercise Considerations. American Journal of Medical Genetics, 160C, 69-79.
https://doi.org/10.1002/ajmg.c.31321

[13]   Ebbink, B.J., Poelman, E., Aarsen, F.K., Plug, I., Régal, L., Muentjes, C., Van Der Beek, N.A.M.E., MH, Van Der Ploeg, A.T. and Van Den Hout, J.M.P. (2018) Classic Infantile Pompe Patients Approaching Adulthood: A Cohort Study on Consequences for the Brain. Developmental Medicine & Child Neurology, 60, 579-586.
https://doi.org/10.1111/dmcn.13740

[14]   Pereira, S.J., Berditchevisky, C.R. and Marie, S.K. (2008) Relato do primeiro paciente brasileiro com a forma infantil da doenca de Pompe tratado com alfa-glicosidase recombinante humana. Jornal de Pediatria, 84, 272-275.
https://doi.org/10.1590/S0021-75572008000300014

[15]   Thomazinho, P.A., Scalco, F.B., Oliveira, M.L.C., Horovitz, D.D.G. and Llerena Jr., J.C. (2017) Motor Development as a Potential Marker to Monitor Infantile Pompe Disease on Enzyme Replacement Therapy. Open Journal of Clinical Diagnostics, 7, 8-19.
https://doi.org/10.4236/ojcd.2017.71002

[16]   Oba-Shinjo, S.M., da Silva, R., Andrade, F.G., et al. (2009) Pompe Disease in a Brazilian Series: Clinical and Molecular Analyses with Identification of Nine New Mutations. Journal of Neurology, 256, 1881-1890.
https://doi.org/10.1007/s00415-009-5219-y

[17]   Mendelsohn, N.J., Messinger, Y.H., Rosenberg, A.S. and Kishnani, P.S. (2009) Elimination of Antibodies to Recombinant Enzyme in Pompe’s Disease. The New England Journal of Medicine, 360, 194-195.
https://doi.org/10.1056/NEJMc0806809

[18]   Messinger, Y.H., Mendelsohn, N.J., Rhead, W., Dimmock, D., Hershkovitz, E., Champion, M., et al. (2012) Successful Immune Tolerance Induction to Enzyme Replacement Therapy in CRIM-Negative Infantile Pompe Disease. Genetics in Medicine, 14, 135-142.
https://doi.org/10.1038/gim.2011.4

[19]   Banugaria, S.G., Prater, S.N., Mackey, J., Das, S., Amalfitano, A., Rosenberg, A.S., et al. (2012) Persistence of High Sustained Antibodies to Enzyme Replacement Therapy Despite Extensive Immunomodulatory Therapy in an Infant with Pompe Disease: Need for Agents to Target Antibody-Secreting Plasma Cells. Molecular Genetics and Metabolism, 105, 677-680.
https://doi.org/10.1016/j.ymgme.2012.01.019

[20]   Yang, C.F., Yang, C.C., Liao, H.C., Huang, L.Y., Chiang, C.C., Ho, H.C., et al. (2016) Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes. The Journal of Pediatrics, 169, 174-180.
https://doi.org/10.1016/j.jpeds.2015.10.078

[21]   Kamphoven, J.H., de Ruiter, M.M., Winkel, L.P., van den Hout, H.M., et al. (2004) Hearing Loss in Infantile Pompe’s Disease and Determination of Underlying Pathology in the Knockout Mouse. Neurobiology of Disease, 16, 14-20.
https://doi.org/10.1016/j.nbd.2003.12.018

[22]   van Capelle, C.I., Goedegebure, A., Homans, N.C., Hoeve, H.L., Reuser, A.J. and van der Ploeg, A.T. (2010) Hearing Loss in Pompe Disease Revisited: Results from a Study of 24 Children. Journal of Inherited Metabolic Disease, 33, 597-602.
https://doi.org/10.1007/s10545-010-9144-0

[23]   Rohrbach, M., Klein, A., Kohli-Wiesner, A., et al. (2010) CRIM-Negative Infantile Pompe Disease: 42-Month Treatment Outcome. Journal of Inherited Metabolic Disease, 33, 751-757.
https://doi.org/10.1007/s10545-010-9209-0

[24]   Nicolino, M., Byrne, B., Wraith, J.E., Leslie, N., Mandel, H., Freyer, D.R., et al. (2009) Clinical Outcomes after Long-Term Treatment with Alglucosidase Alpha in Infants and Children with Advanced Pompe Disease. Genetics in Medicine, 11, 210-219.
https://doi.org/10.1097/GIM.0b013e31819d0996

[25]   van Gelder, C.M., Hoogeveen-Westerveld, M., Kroos, M.A., Plug, I., van der Ploeg, A.T. and Reuser, A.J. (2015) Enzyme Therapy and Immune Response in Relation to CRIM Status: The Dutch Experience in Classic Infantile Pompe Disease. Journal of Inherited Metabolic Disease, 38, 305-314.
https://doi.org/10.1007/s10545-014-9707-6

[26]   Hahn, A., Praetorius, S., Karabul, N., Diebel, J., Schmidt, D., Motz, R., et al. (2015) Outcome of Patients with Classical Infantile Pompe Disease Receiving Enzyme Replacement Therapy in Germany. JIMD Reports, 65-75.

[27]   Broomfield, A., Fletcher, J., Davison, J., Finnegan, N., Fenton, M., Chikermane, A., et al. (2016) Response of 33 UK Patients with Infantile-Onset Pompe Disease to Enzyme Replacement Therapy. Journal of Inherited Metabolic Disease, 39, 261-271.
https://doi.org/10.1007/s10545-015-9898-5

[28]   Chakrapani, A., Vellodi, A., Robinson, P., Jones, S. and Wraith, J.E. (2010) Treatment of Infantile Pompe Disease with Alglucosidase Alpha: The UK Experience. Journal of Inherited Metabolic Disease, 33, 747-750.
https://doi.org/10.1007/s10545-010-9206-3

[29]   Parini, R., de Lorenzo, P., Dardis, A., Burlina, A., Cassio, A., Cavarzere, P., et al. (2018) Long Term Clinical History of an Italian Cohort of Infantile Onset Pompe Disease Treated with Enzyme Replacement Therapy. Orphanet Journal of Rare Diseases, 13, 32.
https://doi.org/10.1186/s13023-018-0771-0

[30]   Al-Hassnan, Z.N., Khalifa, O.A., Bubshait, D.K., Tulbah, S., Alkorashy, M., Alzaidan, H., et al. (2018) The Phenotype, Genotype, and Outcome of Infantile-Onset Pompe Disease in 18 Saudi Patients. Molecular Genetics and Metabolism Reports, 15, 50-54.
https://doi.org/10.1016/j.ymgmr.2018.02.001

[31]   Kishnani, P.S., Corzo, D., Leslie, N.D., et al. (2009) Early Treatment with Alglucosidase Alpha Prolongs Long-Term Survival of Infants with Pompe Disease. Pediatric Research, 66, 329-335.
https://doi.org/10.1203/PDR.0b013e3181b24e94

[32]   Kishnani, P.S., Wuh-Liang, H., Mandel, H., Nicolino, M., Yong, F. and Corzo, D. (2006) A Retrospective Multinational, Multicenter Study of the Natural History of Infantile Pompe Disease. The Journal of Pediatrics, 148, 671-676.
https://doi.org/10.1016/j.jpeds.2005.11.033

[33]   Kroos, M., Hoogeveen-Westerveld, M., van der Ploeg, A. and Reuser, A.J. (2012) The Genotype-Phenotype Correlation in Pompe Disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160, 59-68.
https://doi.org/10.1002/ajmg.c.31318

[34]   van den Berg, L.E., Drost, M.R., Schaart, G., de Laat, J., van Doorn, P.A., van der Ploeg, A.T. and Reuser, A.J. (2013) Muscle Fiber-Type Distribution, Fiber-Type Specific Damage, and the Pompe Disease Phenotype. Journal of Inherited Metabolic Disease, 36, 787-794.
https://doi.org/10.1007/s10545-012-9541-7

[35]   Prater, S.N., Patel, T.T., Buckley, A.F., Mandel, H., Vlodavski, E., Banugaria, S.G., et al. (2013) Skeletal Muscle Pathology of Infantile Pompe Disease during Long-Term Enzyme Replacement Therapy. Orphanet Journal of Rare Diseases, 8, 90.

[36]   Peng, S.S.F., Hwu, W.L., Lee, N.C., Tsai, F.K., Tsai, W.H. and Chien, Y.H. (2016) Slow, Progressive Myopathy in Neonatally Treated Patients with Infantile-Onset Pompe Disease: A Muscle Magnetic Resonance Imaging Study. Orphanet Journal of Rare Diseases, 11, 63.
https://doi.org/10.1186/s13023-016-0446-7

[37]   Wens, S.C.A., van Doeveren, T.E., Lequin, M.H., van Gelder, C.M., Verdijk, R.M., van der Hout, H.J., et al. (2015) Muscle MRI in Classic Infantile Pompe Disease. Journal of Rare Disorders: Diagnosis & Therapy, 1, 10.

[38]   Kroos, M., Hoogeveen-Westerveld, M., Michelakakis, H., Pomponio, R., van der Ploeg, A., Halley, D., Reuser, A.J., et al. (2012) Update of the Pompe Disease Mutation Database with 60 Novel GAA Sequence Variants and Additional Studies on the Functional Effect of 34 Previously Reported Variants. Human Mutation, 33, 1161-1165.
https://doi.org/10.1002/humu.22108

[39]   Cho, A., Kim, S.J., Lim, B.C., Hwang, H., Park, J.D., Kim, G.B., et al. (2012) Infantile Pompe Disease: Clinical and Genetic Characteristics with an Experience of Enzyme Replacement Therapy. Journal of Child Neurology, 27, 319-324.
https://doi.org/10.1177/0883073811420295

[40]   Pittis, M.G., Donnarumma, M., Montalvo, A.L., et al. (2008) Molecular and Functional Characterization of Eight Novel GAA Mutations in Italian Infants with Pompe Disease. Human Mutation, 29, E27-E36.
https://doi.org/10.1002/humu.20753

[41]   Montalvo, A.L., Bembi, B., Donnarumma, M., et al. (2006) Mutation Profile of the GAA Gene in 40 Italian Patients with Late-Onset Glycogen Storage Disease Type II. Human Mutation, 27, 999-1006.
https://doi.org/10.1002/humu.20374

[42]   Moravej, H., Karamizadeh, Z. and Paran, M. (2016) The Outcome of Infantile Onset Pompe Disease in South of Iran. Iran Journal of Pediatrics, 26, e4473.
https://doi.org/10.5812/ijp.4473

[43]   Pellegrini, N., Laforet, P., Orlikowski, D., et al. (2005) Respiratory Insufficiency and Limb Muscle Weakness in Adults with Pompe’s Disease. European Respiratory Journal, 26, 1024-1031.
https://doi.org/10.1183/09031936.05.00020005

[44]   van der Beek, N.A., van Capelle, C.I., van der Velden-van Etten, K.I., Hop, W.C.J., van den Berg, B.W., Reuser, A.J.J., et al. (2011) Rate of Progression and Predictive Factors for Pulmonary Outcome in Children and Adults with Pompe Disease. Molecular Genetics and Metabolism, 104, 129-136.
https://doi.org/10.1016/j.ymgme.2011.06.012

[45]   van der Beek, N.A., de Vries, J.M., Hagemans, M.L., et al. (2012) Clinical Features and Predictors for Disease Natural Progression in Adults with Pompe Disease: A Nationwide Prospective Observational Study. Orphanet Journal of Rare Diseases, 7, 88.
https://doi.org/10.1186/1750-1172-7-88

[46]   Fuller, D.D., ElMallah, M.K., Smith, B.K., Corti, M., Lawson, L.A., Falk, D.J., et al. (2013) The Respiratory Neuromuscular System in Pompe Disease. Respiratory Physiology & Neurobiology, 189, 241-249.
https://doi.org/10.1016/j.resp.2013.06.007

[47]   Sixel, B.S., Silva, L.D., Cavalcanti, N.C., Penque, G.M.C.A., Lisboa, S., Horovitz, D.D.G. and Llerena Jr., J.C. (2017) Manifestacoes respiratórias na doenca de Pompe de início tardio: Uma série de casos no Brasil. The Jornal Brasileiro de Pneumologia, 43, 54-59.
https://doi.org/10.1590/s1806-37562015000000343

[48]   De Ruisseau, L.R., Fuller, D.D., Qiu, K., De Ruisseau, K.C., Donnelly, W.H. Jr., Mah, C., et al. (2009) Neural Deficits Contribute to Respiratory Insufficiency in Pompe Disease. Proceedings of the National Academy of Sciences, 106, 9419-9424.
https://doi.org/10.1073/pnas.0902534106

[49]   Falk, D.J., Todd, A.G., Lee, S., Soustek, M.S., ElMallah, M.K., Fuller, D.D., et al. (2015) Peripheral Nerve and Neuromuscular Junction Pathology in Pompe Disease. Human Molecular Genetics, 24, 625-636.
https://doi.org/10.1093/hmg/ddu476

[50]   Roberts, et al. (2011) The Prevalence and Impact of Scoliosis in Pompe Disease: Lessons Learned from the Pompe Registry. Molecular Genetics and Metabolism, 104, 574-582.
https://doi.org/10.1016/j.ymgme.2011.08.011

[51]   Khatwa, U.A. and Dy, F.J. (2015) Pulmonary Manifestations of Neuromuscular Diseases. Indian Journal of Pediatrics, 82, 841-851.
https://doi.org/10.1007/s12098-015-1814-3

[52]   Hundsberger, T., Rosler, K.M. and Findling, O. (2014) Cessation and Resuming of Alglucosidase Alfa in Pompe Disease: A Retrospective Analysis. Journal of Neurology, 261, 1684-1690.
https://doi.org/10.1007/s00415-014-7402-z

[53]   Amartino, H.M. and Cavagnari, B.M. (2012) Enzyme Replacement Therapy in the Infantile Form of Pompe Disease: Argentinean Experience in a Seven-Year Follow-Up Case. Archivos Argentinos de Pediatria, 110, 323-327.
https://doi.org/10.5546/aap.2012.323

[54]   Fukuda, T., Ewan, L., Bauer, M., Mattaliano, R.J., Zaal, K., Ralston, E., Plotz, P.H. and Raben, N. (2006) Dysfunction of Endocytic and Autophagic Pathways in a Lysosomal Storage Disease. Annals of Neurology, 59, 700-708.
https://doi.org/10.1002/ana.20807

[55]   van den Berg, L.E.M., Zandbergen, A.A., van Capelle, C.I., Vries, J.M., Hop, W.C., van den Hout, J.M., et al. (2010) Low Bone Mass in Pompe Disease—Muscular Strength as a Predictor of Bone Mineral Density. Bone, 47, 643-649.
https://doi.org/10.1016/j.bone.2010.06.021

[56]   Krishnamurthy, V.V., De Armey, S., Mackey, J., Frush, D., et al. (2005) Osteopenia in Infantile Pompe Disease: An Unrecognized Long-Term Complication. Molecular Genetics and Metabolism, 84, A227.

[57]   Case, L.E., Hanna, R., Frush, D.P., Krishnamurthy, V., DeArmey, S., Mackey, J., et al. (2007) Fractures in Children with Pompe Disease: A Potential Long-Term Complication. Pediatric Radiology, 37, 437-445.
https://doi.org/10.1007/s00247-007-0428-y

[58]   Vialle, R., Thévenin-Lemoine, C. and Mary, P. (2013) Neuromuscular Scoliosis. Orthopaedics & Traumatology: Surgery & Research, 99S, S124-S139.
https://doi.org/10.1016/j.otsr.2012.11.002

[59]   Moreira, C.L.M. (2012) A Fisioterapia integrada a uma política pública em saúde: O estudo da funcionalidade de pacientes do Centro de Referência em Osteogênese Imperfeita do Rio de Janeiro. Tese de Doutorado, Pós-Graduacao em Saúde da Crianca e da Mulher, Instituto Nacional de Saúde da Mulher, da Crianca e do Adolescente Fernandes Figueira, Rio de Janeiro.

[60]   van Capelle, C.I., van der Meijden, C.J., van den Hout J.M.P., Jaeken, J., Baethmann, M., Voit, T., et al. (2016) Childhood Pompe Disease: Clinical Spectrum and Genotype in 31 Patients. Orphanet Journal of Rare Diseases, 11, 65.
https://doi.org/10.1186/s13023-016-0442-y

[61]   Spiridigliozzi, G.A., Keeling, L.A., Stefanescu, M., Li, C., Austin, S. and Kishnani, P.S. (2017) Cognitive and Academic Outcomes in Long-Term Survivors of Infantile-Onset Pompe Disease: A Longitudinal Follow-Up. Molecular Genetics and Metabolism, 121, 127-137.
https://doi.org/10.1016/j.ymgme.2017.04.014

[62]   Kishnani, P.S. and Beckemeyer, A.A. (2014) New Therapeutic Approaches for Pompe Disease: Enzyme Replacement Therapy and Beyond. Pediatric Endocrinology Reviews, 1, 114-124.

[63]   Owens, P., Wong, M., Bhattacharya, K. and Ellaway, C. (2018) Infantile-Onset Pompe Disease: A Case Series Highlighting Early Clinical Features, Spectrum of Disease Severity and Treatment Response. Journal of Paediatrics and Child Health, 54, 1255-1261.
https://doi.org/10.1111/jpc.14070

[64]   Kishnani, P.S., Beckemeyer, A.A. and Mendelsohn, N.J. (2012) The New Era of Pompe Disease: Advances in the Detection, Understanding of the Phenotypic Spectrum, Pathophysiology, and Management. American Journal of Medical Genetics, 160C, 1-7.
https://doi.org/10.1002/ajmg.c.31324

 
 
Top